Take a look through some of the notable data presentations at this year's ESMO Congress.
|Articles|January 1, 2004
Medicare reform: Short-term gain but long-term pain
Author(s)Ray Painter, MD
Be prepared for a short-term gain that may be a long-term pain. The AmericanMedical Association has claimed a major political victory with passage ofthe Medicare Prescription Drug Improvement and Modernization Act of 2003,and I certainly hope the AMA is correct. Certainly the pay increase overthe next 2 years is great. However, I have concerns about many of the otherissues addressed in the bill.
Advertisement
Advertisement
Related to this article
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
The agency issued a PDUFA target action date of June 14, 2027.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.
Vignesh Packiam, MD, discusses strategies to manage intravesical therapy toxicity in NMIBC, improve treatment tolerability, and preserve bladder function.
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
Advertisement
Advertisement
Trending on Urology Times
1
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
2
Jeffrey M. Spier, MD, on the evidence for reduced-dose enzalutamide
3
Prostate Cancer Case Review: Selecting Radioligand Therapy Candidates
4
Prostate Cancer Case Review: PSMA PET Before Definitive Therapy
5